Significant efforts in the past three decades have been made to advance the treatment of patients with end-stage heart disease using implantable, durable, mechanically assisted circulatory support technology. Despite many advances in pump technology, there is a continued appreciation of the complex interplay between multiple factors in these patients, which often detracts from the most desirable outcomes. Optimizing neurological outcomes in the situation of an elective implantation of a left ventricular assist device is of the utmost importance not only for patient outcomes but also for reassurance to providers to consider this therapy for the treatment of advanced heart failure. In order to achieve the best outcomes possible, the provider must optimize the dynamic and highly interconnected system into which the device was placed. Herein, we describe “The Continuous-Flow Pump Disease” as a biosystem representing a great paradox. While this is a therapy that has proven effective and durable in treating advanced heart failure, it also imparts de novo and unintended clinical conditions requiring optimization. Adverse neurological outcomes are at the intersection of multiple pump-, provider-, and patient-related factors, which all have inherent challenges to obtaining homeostasis. However, in any complex system, the more understanding and predictability that exists, the less that an outcome is left to chance and the more that they are expected.